AAAAAA
Results: 1-25/36
Authors:
Estines, O
Revuz, J
Wolkenstein, P
Bressieux, JM
Roujeau, JC
Cosnes, A
Citation: O. Estines et al., Sarcoidosis: thalidomide treatment in ten patients, ANN DER VEN, 128(5), 2001, pp. 611-613
Authors:
Mahe, E
Zeller, J
Wechsler, J
Wolkenstein, P
Revuz, J
Citation: E. Mahe et al., Large hairy pigmented spots in neurofibromatosis type I: an atypical aspect of neurofibromas., ANN DER VEN, 128(5), 2001, pp. 619-621
Authors:
Pinson, S
Creange, A
Barbarot, S
Stalder, JF
Chaix, Y
Rodriguez, D
Sanson, M
Bernheim, A
D'Incan, M
Doz, F
Stoll, C
Combemale, P
Kalifa, C
Zeller, J
Teillac-Hamel, D
Lyonnet, S
Zerah, M
Lacour, JP
Guillot, B
Wolkenstein, P
Citation: S. Pinson et al., Neurofibromatosis 1: recommendations for management, ANN DER VEN, 128(4), 2001, pp. 567-575
Authors:
Bellivier, F
Laplanche, JL
Fournier, G
Wolkenstein, P
Citation: F. Bellivier et al., Serotonin transporter gene polymorphism and psychiatric disorders in NF1 patients, AM J MED G, 105(8), 2001, pp. 758-760
Authors:
Moreno, JC
Mathoret, C
Lantieri, L
Zeller, J
Revuz, J
Wolkenstein, P
Citation: Jc. Moreno et al., Carbon dioxide laser for removal of multiple cutaneous neurofibromas, BR J DERM, 144(5), 2001, pp. 1096-1098
Authors:
Richette, P
Claudepierre, P
Voisin, MC
Le Mouel, S
Wolkenstein, P
Rahmouni, A
Chevalier, X
Citation: P. Richette et al., Hemarthrosis - An unusual complication of type 1 neurofibromatosis, ARTH RHEUM, 44(9), 2001, pp. 2134-2137
Authors:
Leroy, K
Dumas, V
Martin-Garcia, N
Falzone, MC
Voisin, MC
Wechsler, J
Revuz, J
Creange, A
Levy, E
Lantieri, L
Zeller, J
Wolkenstein, P
Citation: K. Leroy et al., Malignant peripheral nerve sheath tumors associated with neurofibromatosistype 1 - A clinicopathologic and molecular study of 17 patients, ARCH DERMAT, 137(7), 2001, pp. 908-913
Authors:
Wolkenstein, P
Mitrofanoff, M
Lantieri, L
Zeller, J
Wechsler, J
Boui, M
Revuz, J
Mansat, E
Stalder, JF
Citation: P. Wolkenstein et al., Bleeding: A complication of neurofibromatosis 1 tumors, ARCH DERMAT, 137(2), 2001, pp. 233-234
Authors:
Wolkenstein, P
Zeller, J
Revuz, J
Ecosse, E
Leplege, A
Citation: P. Wolkenstein et al., Quality-of-life impairment in neurofibromatosis type 1 - A cross-sectionalstudy of 128 cases, ARCH DERMAT, 137(11), 2001, pp. 1421-1425
Authors:
Wolkenstein, P
Loriot, MA
Aractingi, S
Cabelguenne, A
Beaune, P
Chosidow, O
Citation: P. Wolkenstein et al., Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS, PHARMACOGEN, 10(9), 2000, pp. 821-828
Authors:
Girou, E
Azar, J
Wolkenstein, P
Cizeau, M
Brun-Buisson, C
Roujeau, JC
Citation: E. Girou et al., Comparison of systematic versus selective screening for methicillin-resistant Staphylococcus aureus carriage in a high-risk dermatology ward, INFECT CONT, 21(9), 2000, pp. 583-587
Authors:
Wolkenstein, P
Revuz, J
Citation: P. Wolkenstein et J. Revuz, Toxic epidermal necrolysis, DERM CLIN, 18(3), 2000, pp. 485
Authors:
Wolkenstein, P
Citation: P. Wolkenstein, Is systematic excision of pigmented spots on the plantar aspect of the foot warranted?, ANN DER VEN, 127(6-7), 2000, pp. 648-651
Authors:
Machet, L
Wolkenstein, P
Vaillant, L
Citation: L. Machet et al., Topical antibiotics used in dermatology: efficiency. indications and adverse events, ANN DER VEN, 127(4), 2000, pp. 425-431
Authors:
Bodak, N
Wolkenstein, P
Citation: N. Bodak et P. Wolkenstein, Digital clubbing, ANN DER VEN, 127(3), 2000, pp. 312-316
Authors:
Wolkenstein, P
Citation: P. Wolkenstein, Cross-cultural adjustment of quality-of-life scales: A need and an urgencyin dermatology, ANN DER VEN, 127, 2000, pp. 23-24
Authors:
Wolkenstein, P
Citation: P. Wolkenstein, Centers for disease control and prevention (CDC), ANN DER VEN, 127(1), 2000, pp. 131-131
Authors:
Lin, AE
Birch, PH
Korf, BR
Tenconi, B
Niimura, M
Poyhonen, M
Uhas, KA
Sigorini, M
Virdis, R
Romano, C
Bonioli, E
Wolkenstein, P
Pivnick, EK
Lawrence, M
Friedman, JM
Citation: Ae. Lin et al., Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1, AM J MED G, 95(2), 2000, pp. 108-117
Authors:
Bastuji-Garin, S
Fouchard, N
Bertocchi, M
Roujeau, JC
Revuz, J
Wolkenstein, P
Citation: S. Bastuji-garin et al., SCORTEN: A severity-of-illness score for toxic epidermal necrolysis, J INVES DER, 115(2), 2000, pp. 149-153
Authors:
Richard, MA
Grob, JJ
Avril, MF
Delaunay, M
Gouvernet, J
Wolkenstein, P
Souteyrand, P
Dreno, B
Bonerandi, JJ
Dalac, S
Machet, L
Guillaume, JC
Chevrant-Breton, J
Vilmer, C
Aubin, F
Guillot, B
Beylot-Barry, M
Lok, C
Raison-Peyron, N
Chemaly, P
Citation: Ma. Richard et al., Delays in diagnosis and melanoma prognosis (I): The role of patients, INT J CANC, 89(3), 2000, pp. 271-279
Authors:
Richard, MA
Grob, JJ
Avril, MF
Delaunay, M
Gouvernet, J
Wolkenstein, P
Souteyrand, P
Dreno, B
Bonerandi, JJ
Dalac, S
Machet, L
Guillaume, JC
Chevrant-Breton, J
Vilmer, C
Aubin, F
Guillot, B
Beylot-Barry, M
Lok, C
Raison-Peyron, N
Chemaly, P
Citation: Ma. Richard et al., Delays in diagnosis and melanoma prognosis (II): The role of doctors, INT J CANC, 89(3), 2000, pp. 280-285
Authors:
Beneton, N
Wolkenstein, P
Bagot, M
Cosnes, A
Wechsler, J
Roujeau, JC
Revuz, J
Citation: N. Beneton et al., Amicrobial pustulosis associated with autoimmune diseases: healing with zinc supplementation, BR J DERM, 143(6), 2000, pp. 1306-1310
Authors:
Wolkenstein, P
Durand-Zaleski, I
Moreno, JC
Zeller, J
Hemery, F
Revuz, J
Citation: P. Wolkenstein et al., Cost evaluation of the medical management of neurofibromatosis 1: a prospective study on 201 patients, BR J DERM, 142(6), 2000, pp. 1166-1170
Authors:
Wolkenstein, P
Revuz, J
Citation: P. Wolkenstein et J. Revuz, Allergic emergencies encountered by the dermatologist - Severe cutaneous adverse drug reactions, CL R ALL IM, 17(4), 1999, pp. 497-511
Authors:
Wolkenstein, P
Zeller, J
Citation: P. Wolkenstein et J. Zeller, Clinical work-up for neurofibromatosis type 1 (NF1), PRESSE MED, 28(39), 1999, pp. 2174-2180